SBRT联合ADT对比常规/中度分割放疗联合ADT治疗不良风险前列腺癌
基于美国国家癌症数据库分析558例接受SBRT联合ADT与40,797例接受常规或中度低分割EBRT联合ADT的局限期前列腺癌患者,按NCCN不良中危和高危分层,中位随访74个月,两组6年总生存无差异,多因素分析死亡风险亦无差异,支持NCCN将SBRT列为更高风险男性的非首选方案。
要点
- SBRT联合ADT与EBRT联合ADT在不良中危和高危前列腺癌中6年OS无差异。
- 敏感性分析限定NCCN首选剂量分割、无合并症或<65岁人群,仍无生存差异。
核心结论
- 在研究局限性内,SBRT联合ADT与标准EBRT联合ADT治疗不良中危或高危前列腺癌的生存无差异。
研究设计与样本
- 回顾性分析美国国家癌症数据库2004-2016年接受外照射放疗联合ADT的局限期前列腺癌男性(>40岁)。
- 排除缺乏ADT或风险分层数据者,纳入SBRT组558例,常规或中度低分割EBRT组40,797例。
- 按NCCN标准分为不良中危(UIR)和高危(HR),采用Kaplan-Meier和Cox比例风险模型比较总生存,调整年龄、种族和合并症指数。
主要发现
- 中位随访74个月,无论风险组,SBRT与EBRT组估计6年OS均无差异。
- 敏感性分析限定NCCN首选剂量分割、无合并症或<65岁人群,两组UIR和HR均无生存差异。
关键数值与推荐
- NCCN风险分层标准用于定义不良中危和高危。
- SBRT组558例,EBRT组40,797例。
- 中位随访74个月,估计6年OS无差异。
临床怎么用
- 对于不良中危或高危前列腺癌,SBRT联合ADT可作为EBRT联合ADT之外的考虑选项。
- 结果支持NCCN指南将SBRT列为更高风险男性的非首选方案。
- 需以前瞻性研究进一步验证该推荐证据。
局限性
- 研究为回顾性数据库分析,存在选择偏倚和未测量混杂。
- 缺乏前列腺癌特异性生存、生化控制及毒性等终点。
- SBRT组样本量远小于EBRT组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ultrahypofractionation using stereotactic body radiotherapy (SBRT) is an increasingly utilized technique for men with prostate cancer (PC). The comparative efficacy of SBRT plus androgen deprivation therapy (ADT) compared to fractionated radiotherapy (EBRT) plus ADT in higher-risk prostate cancer is unknown. METHODS: Men > 40 years old with localized PC treated with external beam radiation and concomitant ADT for curative intent between 2004 and 2016 were analyzed from the National Cancer Database. Patients who lacked ADT or risk stratification data were excluded. 558 men treated with SBRT versus 40,797 men treated with conventional or moderately hypofractionated EBRT were included. Patients were stratified by unfavorable intermediate (UIR) and high (HR) risk using NCCN criteria. Kaplan Meier and Cox proportional hazards were used to compare overall survival (OS) between RT modality, adjusting for age, race, and comorbidity index. RESULTS: With a median follow up of 74 months, there was no difference in estimated 6-year OS between men treated with SBRT versus EBRT regardless of risk group. On multivariable analysis, there was no difference in risk of death for men treated with SBRT compared to EBRT (UIR: adjusted HR 1.09, 95% CI 0.68-1.74, p = .72; HR: adjusted HR 0.93, 95% CI 0.76-1.14, p = .51). On sensitivity analyses, when confining the cohort to men treated with NCCN-preferred dose fractionations, with no comorbidities, or < 65 years old, there remained no survival difference between treatment groups for both UIR and HR. CONCLUSION: Within study limitations, we found no difference in survival between SBRT+ADT and standard of care EBRT+ADT for UIR or HR PC. These results support recent NCCN guideline updates, which include SBRT as a non-preferred option for higher risk men. Prospective validation would further strengthen the evidence basis behind these recommendations.
引用
- Patel SA, Switchenko JM, Fischer-Valuck B, et al. Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer. Radiat Oncol. 2020. PMID: 32933541. doi:10.1186/s13014-020-01658-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。